Alkem Laboratories Disputes ₹333.38 Crore Tax Assessment Order for AY 2023-24
Alkem Laboratories received an income tax assessment order disputing ₹333.38 crores for AY 2023-24, involving disallowance of section 80IE deduction and transfer pricing adjustments. The order dated 13th April 2026 was received on 24th April 2026 from Deputy Commissioner of Income Tax, Mumbai. Despite the substantial disputed amount, the company expects no cash outflow due to MAT credit utilization and plans to appeal, citing adequate legal grounds to contest the assessment.
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories has received an income tax assessment order disputing ₹333.38 crores for the assessment year 2023-24, the pharmaceutical company disclosed under Regulation 30 of SEBI LODR Regulations on 24th April 2026.
Assessment Order Details
The Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai issued the assessment order dated 13th April 2026 under section 143(3) read with section 144C(3) of the Income Tax Act, 1961. The order was received by the company on 24th April 2026.
| Parameter | Details |
|---|---|
| Assessment Year | 2023-24 |
| Disputed Tax Amount | ₹333.38 Crores |
| Order Date | 13th April 2026 |
| Receipt Date | 24th April 2026 |
| Issuing Authority | Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai |
Nature of Disputes
The income tax authority has raised two primary issues in the assessment order:
- Section 80IE Deduction: Disallowance of part of deduction claimed under section 80IE of the Income Tax Act, 1961
- Transfer Pricing Adjustments: Additional adjustments related to transfer pricing matters
These adjustments have resulted in the disputed tax amount of ₹333.38 crores being raised by the IT authority.
Financial Impact Assessment
| Impact Area | Status |
|---|---|
| Expected Cash Outflow | Nil |
| Reason | Utilization of available MAT credit |
| Material Financial Impact | None expected |
| Operational Impact | No disruption anticipated |
Despite the substantial disputed amount, Alkem Laboratories has clarified that no amount is payable by the company due to the utilization of available Minimum Alternate Tax (MAT) credit. The company has stated there is no material impact on its financial, operational, or other activities due to this order.
Company's Response Strategy
Alkem Laboratories has expressed confidence in its position regarding the disputed assessment. The company believes that the dispute raised in the order is not tenable and maintains that it has adequate factual and legal grounds to substantiate its position. The pharmaceutical manufacturer has indicated its intention to pursue an appeal against the assessment order under applicable laws.
This development follows the company's earlier intimation dated 14th September 2023, suggesting ongoing interactions with tax authorities. The disclosure has been made available on the company's website at www.alkemlabs.com as part of its transparency commitments to stakeholders.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.08% | -4.26% | +0.89% | -3.62% | +2.75% | +91.00% |
How might the outcome of Alkem's appeal influence transfer pricing scrutiny for other pharmaceutical companies with similar international operations?
What impact could prolonged tax litigation have on Alkem's future MAT credit availability and cash flow planning?
Will this assessment order prompt Alkem to restructure its Section 80IE eligible operations or transfer pricing policies going forward?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
